This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Maternally inherited diabetes and deafness (MIDD)

Authoring team

  • caused by a mutation in mitochondrial DNA (3243 tRNA)
    • mitochondrial DNA is contributed to the embryo by the oocyte and not by spermatozoa, and therefore this disease is inherited from maternal family members only

  • diabetes is a non insulin dependent type that usually presents before the age of 40 years
    • due to a defect in beta cell function with normal insulin sensitivity
    • associated deafness is sensorineural and develops in most of the diabetic subjects
      • hearing loss is variable
        • of these diabetic patients carrying the mitochondrial DNA mutation at position 3243, 75% experience sensorineural hearing loss
        • associated hearing loss with diabetes is typically more common and more quickly declining in men than in women

  • MIDD may have other multi-organ features: for example, elevated serum lactate, neuromuscular and cardiac problems, pigmented retinopathy, and nephropathy with proteinuria

Reference:

  • Murphy R et al. Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabet. Med. 2008, 25(4),383-99.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.